» Articles » PMID: 23615186

Self-inactivating MLV Vectors Have a Reduced Genotoxic Profile in Human Epidermal Keratinocytes

Overview
Journal Gene Ther
Date 2013 Apr 26
PMID 23615186
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Transplantation of epithelia derived from keratinocyte stem cells transduced by retroviral vectors is a potential therapy for epidermolysis bullosa (EB), a family of inherited skin adhesion defects. The biosafety characteristics of retroviral vectors in keratinocytes are, however, poorly defined. We developed self-inactivating (SIN) vectors derived from the Moloney murine leukemia (MLV) and the human immunodeficiency (HIV) viruses expressing therapeutic levels of LAMB3, a transgene defective in junctional EB, and tested their integration profile in human primary keratinocytes. The SIN-HIV vector showed the expected preference for transcribed genes while the SIN-MLV vector integrated preferentially in regulatory elements, but showed a significantly lower tendency to target cell growth-related genes, transcription start sites and epigenetically defined promoters compared with a wild-type MLV vector in an epithelial cell context. A quantitative gene expression assay in individual keratinocyte clones showed that MLV-derived vectors deregulate expression of targeted genes at a lower frequency than in hematopoietic cells, and that the SIN-MLV design has the lowest activity compared to both MLV and SIN-HIV vectors. This study indicates that SIN-MLV vectors may have a better safety profile in keratinocyte than in hematopoietic cells, and be a reasonable alternative to lentiviral vectors for gene therapy of inherited skin disorders.

Citing Articles

A cellular disease model toward gene therapy of -dependent lamellar ichthyosis.

Sercia L, Romano O, Marini G, Enzo E, Forcato M, De Rosa L Mol Ther Methods Clin Dev. 2024; 32(3):101311.

PMID: 39234443 PMC: 11372595. DOI: 10.1016/j.omtm.2024.101311.


Optimal delivery of RNA interference by viral vectors for cancer therapy.

Wong B, Birtch R, Rezaei R, Jamieson T, Crupi M, Diallo J Mol Ther. 2023; 31(11):3127-3145.

PMID: 37735876 PMC: 10638062. DOI: 10.1016/j.ymthe.2023.09.012.


Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa.

De Rosa L, Enzo E, Zardi G, Bodemer C, Magnoni C, Schneider H Front Genet. 2021; 12:705019.

PMID: 34539738 PMC: 8440932. DOI: 10.3389/fgene.2021.705019.


Interaction of the NRF2 and p63 transcription factors promotes keratinocyte proliferation in the epidermis.

Kurinna S, Seltmann K, Bachmann A, Schwendimann A, Thiagarajan L, Hennig P Nucleic Acids Res. 2021; 49(7):3748-3763.

PMID: 33764436 PMC: 8053124. DOI: 10.1093/nar/gkab167.


Delivery technologies for in utero gene therapy.

Palanki R, Peranteau W, Mitchell M Adv Drug Deliv Rev. 2020; 169:51-62.

PMID: 33181188 PMC: 7855052. DOI: 10.1016/j.addr.2020.11.002.